Corline Biomedical AB (STO:CLBIO)

Market Cap	401.14M +89.6%
Revenue (ttm)	8.59M -50.3%
Net Income	-14.71M
EPS	-0.59
Shares Out	26.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,102
Average Volume	13,636
Open	15.50
Previous Close	16.05
Day's Range	15.15 - 15.90
52-Week Range	9.48 - 27.20
Beta	0.30
RSI	40.34
Earnings Date	May 8, 2026

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 12
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CLBIO

Financial Performance

In 2025, Corline Biomedical AB's revenue was 8.59 million, a decrease of -50.29% compared to the previous year's 17.27 million. Losses were -14.71 million, -36.56% less than in 2024.